Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 5/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 7/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.35 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.35 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.34 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.34 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.34 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.34 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.34 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14815208 | 0.89 | LIPE (0.44) | LIPESCN9AHRH3SCN10ALIPG | |
| SCHEMBL14814731 | 0.88 | LIPE (0.38) | LIPESCN9AHRH3SCN10ALIPG | |
| SCHEMBL14814623 | 0.86 | LIPE (0.38) | LIPESCN9AHRH3HSD11B1PSEN1 | |
| SCHEMBL14814672 | 0.86 | LIPE (0.39) | LIPESCN9AHRH3SCN10ALIPG | |
| SCHEMBL14814654 | 0.86 | EPHX2 (0.38) | LIPESCN9AHRH3SCN10ALIPG | |
| SCHEMBL14814621 | 0.86 | LIPE (0.39) | LIPESCN9AHRH3SCN10ALIPG | |
| SCHEMBL14815053 | 0.86 | LIPE (0.39) | LIPESCN9AHRH3SCN10ALIPG | |
| SCHEMBL14815113 | 0.85 | LIPE (0.36) | LIPESCN9AHRH3SCN10ALIPG | |
| SCHEMBL14814787 | 0.85 | LIPE (0.36) | LIPESCN9AHRH3SCN10ALIPG | |
| SCHEMBL14815274 | 0.84 | LIPE (0.41) | LIPESCN9AHRH3SCN10ALIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8669255-B2 | Substituted octahydropyrrolo[1,2-a]pyrazines as calcium channel blockers | ABBVIE INC. (US) | 2014-03-11 | — | — | US | claimed |
| US-8669255-B2 | Substituted octahydropyrrolo[1,2-a]pyrazines as calcium channel blockers | ABBVIE INC. (US) | 2014-03-11 | — | — | US | disclosed |
| US-20130085142-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS | ABBVIE INC. (US) | 2013-04-04 | — | — | US | disclosed |
| WO-2013049164-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS | ABBVIE INC. (US) | 2013-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085142-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, CACNA1E, CACNA1D | LIPE 4720/4885SCN9A 298/4885HRH3 1244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.